1 withdrawn. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Withdrawn 1 |
Follow CBNPC Cancer: new trials by email Literature Review of CBNPC Cancer trials Research Report on CBNPC Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures Atezolizumab 1200 mg IV, Tiragolumab 600 mg IV - Metastatic Cancer Lung, Advanced Lung Cancer | Phase 2 | Withdrawn | Gustave Roussy, Cancer Campus, Grand Paris | 2025-01-30 | 2026-03-23 |
Lung Neoplasms (1)
Lung Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Thoracic Neoplasms (1)
Tiragolumab (1) · atezolizumab (1)
Gustave Roussy, Cancer Campus, Grand Paris (1)
2023 (1)